Direct Oral Anticoagulant Failures in Atrial Fibrillation With Stroke: Retrospective Admission Analysis and Novel Classification System
The Neurohospitalist · 2023-07 · 13 (3) · 256-265
DOI: 10.1177/19418744231161390 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Neurohospitalist, online erschienen am 12.05.2023. Verfasst von David Z Rose und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaganfall
Abstract (Originalsprache)
Introduction
Breakthrough acute ischemic stroke (AIS) in patients with known, nonvalvular Atrial Fibrillation (AF), on Direct Oral Anticoagulants (DOAC), is an ongoing clinical conundrum. Switching anticoagulants was shown to be ineffective in preventing recurrent AIS. Systematic, patient-level chart review of so-called “DOAC failures” may offer insight into this phenomenon.
Methods
We conducted an IRB-approved, 6-year, retrospective study of AIS admissions, already prescribed DOAC for known AF. We sought plausible, alternative reasons for the AIS using a novel classification schema, CLAMP: C for Compliance concerns, L for Lacunes (small-vessel disease), A for Arteriopathy (atherosclerosis, web, or vasculitis), M for Malignancy, and P for Patent Foramen Ovale (PFO). These categories were labeled as DOAC “Pseudo-failures.” Conversely, absence of CLAMP variables were labeled as DOAC “Crypto-failures” conceivably from AF itself (“atriopathy”) or pharmacokinetic/pharmacogenomic dysfunction (ie, altered DOAC absorption, clearance, metabolism, or genetic polymorphisms). Forward logistic regression analysis was performed on prespecified DOAC subgroups.
Results
Of 4890 AIS admissions, 606 had AF, and 87 were previously prescribed DOAC (14.4% overall DOAC failure rate, 2.4% annualized over 6 years). Pseudo-failures comprised 77%: Compliance concerns (48.9%), Lacunes (5.7%), Arteriopathy (17.0%), Malignancy (26.1%), and PFO (2.3%). Crypto-failures comprised 23%, had lower CHADSVASc scores (AOR = .65, P = .013), and occurred more with rivaroxaban (41%) than apixaban (16%) or dabigatran (5.6%).
Conclusion
In AIS patients with known AF, DOAC Pseudo-failures, with identified alternate etiologies, are 3 times more likely than DOAC Crypto-failures. The CLAMP schema represents a novel approach to diagnostic classification and therapeutic adjustments in patients already prescribed DOAC for AF.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
- Ascendant Biotech Inc., Foster City, CA, USA.
- University of South Dakota, Sioux Falls, SD, USA.
- University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
- College of Public Health, University of South Florida, Tampa, FL, USA.
- Providence Spokane Neuroscience Institute, Spokane, WA, USA.
ORCID-Profile: David Z Rose, Jane Y Chang
Zitieren
APA
Rose, D. Z., Chang, J. Y., Yi, X., Kip, K., Lu, Y., Hilker, N. C., & Beltagy, A. (2023). Direct Oral Anticoagulant Failures in Atrial Fibrillation With Stroke: Retrospective Admission Analysis and Novel Classification System. The Neurohospitalist, 13(3), 256-265. https://doi.org/10.1177/19418744231161390
Vancouver
Rose DZ, Chang JY, Yi X, Kip K, Lu Y, Hilker NC, et al. Direct Oral Anticoagulant Failures in Atrial Fibrillation With Stroke: Retrospective Admission Analysis and Novel Classification System. The Neurohospitalist. 2023;13(3):256-265. doi:10.1177/19418744231161390
BibTeX
@article{Rose2023,
author = {Rose, David Z and Chang, Jane Y and Yi, Xiyan and Kip, Kevin and Lu, Yuanyuan and Hilker, N Corbin and Beltagy, Abdelrahman},
title = {Direct Oral Anticoagulant Failures in Atrial Fibrillation With Stroke: Retrospective Admission Analysis and Novel Classification System},
journal = {The Neurohospitalist},
year = {2023},
volume = {13},
number = {3},
pages = {256--265},
doi = {10.1177/19418744231161390}
}
EUVIMED